Popular Articles

Biological Warfare In Bacteria Offers Hope For New Antibiotics
Scientists are to study a group of proteins that are highly effective at killing bacteria and which could hold the key to developing new types of antibiotics.

More Women Seek Nonprescription Remedies For Menopause Symptoms
Over-the-counter remedies for menopause symptoms are growing in popularity among some women who fear potential risks from prescription hormone replacement therapy, the New York Times reports. According to the Times, the market for alternative therapies -- such as natural supplements and topical creams -- jumped in 2002 after initial results from the Women"s Health Initiative suggested that HRT could increase risk for heart disease, cancer, stroke and blood clots. Gynecologists estimate that about one-third of menopausal women are treated with conventional prescription hormones, and about one-third are treated with bio-identical hormones -- plant-derived synthetic hormones that mimic the molecular structure of human hormones. The remaining one-third either do not seek therapy for symptoms, are not bothered by symptoms or use over-the-counter therapies. There are more than 500 over-the-counter products available that claim to alleviate menopause symptoms, the Times reports. The treatments include such products as teas, low-dose progesterone creams, black cohosh capsules and phytoestrogens derived from soy and red clover, according to the Times. According to Nutrition Business Journal, the U.S. dietary supplement market associated with menopause increased from $211 million in 1999 to $337 million in 2007.Some studies have raised doubts about the safety and effectiveness of the over-the-counter remedies. Todd Cooperman -- director of consumerLab.com, a private nutrition product-testing lab -- said that his company"s study of more than one dozen products found that five failed to gain the lab"s approval because of problems such as inaccurate labeling or tainted ingredients. The Center for Botanical Dietary Supplements Research this fall is expected to release the results of a study, sponsored by the National Institutes of Health, that aims to determine the efficacy of the ingredients associated with menopause symptom relief. Some studies have questioned the efficacy of progesterone creams, which some experts contend can gather in fat cells and disrupt the production and synthesis of other hormones. Other experts maintain that the products are safe if properly used. Theresa Ramsey, director of the Center for Natural Healing in Arizona, said, "I think over all these products are generally safe, but must be taken in the right circumstances and in conjunction with a mindfully healthy approach to life if they are going to be effective at all" (Sweeney, New York Times, 7/2).
News of the day
Abortion Could Prove Divisive For Health Reform, Too
An ultimatum against using federal money for abortion procedures could reopen the politically treacherous rift over the issue, creating yet another obstacle for congressional Democrats to overcome if they are to achieve their health reform goals, Time reports. "While current versions of the [health reform] legislation do not address the abortion issue at all, late last month 19 anti-abortion Democrats in the House sent a letter to Speaker Nancy Pelosi, warning "we cannot support any health care reform proposal unless it explicitly excludes abortion from the scope of any government-defined or subsidized health insurance plan.""
Nutrition

ChemGenex To Present Pivotal Data In T315I Positive CML Patients As Oral Presentation At ASCO

ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced that updated clinical data from the registration-directed clinical trial of omacetaxine will be presented as an oral presentation at the forthcoming American Society of Clinical Oncology (ASCO) 45th Annual Meeting in Orlando, Florida. Data from the pivotal study on the use of omacetaxine in chronic myeloid leukemia (CML) patients who have failed imatinib and who harbor the T315I mutation, will be given at 11:30 am on Monday 1st June, by Dr. Jorge Cortes, MD, Professor of Medicine and Deputy Chair in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center. In addition, a poster on the company"s complementary phase 2 study investigating the potential use of omacetaxine in CML patients with resistance to multiple tyrosine kinase inhibitors (TKIs), will be presented between 5-6 pm on Friday 29th May by Dr. Meir Wetzler MD, Chief of the Division of Leukemia, School of Medicine and Biomedical Sciences, University at Buffalo, Roswell Park Cancer Institute. Commenting on today"s publication of the final program for ASCO, Greg Collier, Ph.D., Managing Director and Chief Executive Officer of ChemGenex said, "We are delighted that our late stage product candidate, omacetaxine, will be presented at a podium session during this prestigious conference." About Omacetaxine Omacetaxine mepesuccinate is a first-in-class cetaxine with demonstrated clinical activity as a single agent in a range of hematological malignancies. Omacetaxine has a novel mechanism of action, and induces apoptosis by inhibition of protein synthesis, particularly Mcl-1. As omacetaxine acts independently of tyrosine kinase inhibitors, it may have a therapeutic advantage for patients who have developed resistance to TKIs. Omacetaxine is administered subcutaneously. ChemGenex Pharmaceuticals Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):